SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales moved down -36.57% to Rs. 72.74 millions for the December 2025 quarter as compared to Rs. 114.67 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2025 is Rs. -31.26 millions as compared to Net Loss of Rs. -77.39 millions of corresponding quarter ended December 2024 Operating profit Margin for the quarter ended December 2025 improved to 3.02% as compared to -44.65% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 72.74 114.67 -36.57 169.22 372.11 -54.52 433.12 504.22 -14.10
Other Income 0.04 2.51 -98.41 0.23 3.71 -93.80 7.09 4.51 57.21
PBIDT 3.02 -44.65 -106.76 -45.59 -92.52 -50.72 -143.21 -82.72 73.13
Interest 17.93 15.57 15.16 51.76 43.00 20.37 59.14 46.89 26.12
PBDT -14.91 -60.22 -75.24 -97.35 -135.52 -28.17 -202.35 -129.61 56.12
Depreciation 16.35 17.17 -4.78 48.58 51.19 -5.10 66.89 67.66 -1.14
PBT -31.26 -77.39 -59.61 -145.93 -186.71 -21.84 -269.24 -197.27 36.48
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -31.26 -77.39 -59.61 -145.93 -186.71 -21.84 -269.39 -197.27 36.56
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) 4.15 -38.94 -110.66 -26.94 -24.86 8.36 -33.06 -16.41 101.55

Krebs Biochem.&Inds Share Price

60.00 -2.15 (-3.46%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×